-
Mashup Score: 0
A proteogenomic analysis found savolitinib plus osimertinib elicited a response in patients with EGFR-mutated, MET-amplified advanced NSCLC.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
“Savolitinib plus osimertinib demonstrated clinical activity, with savolitinib plus placebo showing lower clinical activity,” lead study author James Chih-Hsin Yang, MD, PhD. #NSCLC #AACR24 | @AACR https://t.co/RsgfB5RC87